FAKTOR-OPTIONSSCHEIN - GENMAB | Market Closed - Börse Stuttgart 12:18:08 01/06/2024 am IST | ||
| 0.31 EUR | -.--% |
|
| 1 month | -3.12% | ||
| 3 months | -6.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.31 | -.--% |
| 30/24/30 | 0.31 | -3.13% |
| 29/24/29 | 0.32 | +10.34% |
| 28/24/28 | 0.29 | -3.33% |
| 27/24/27 | 0.3 | -3.23% |
Delayed Quote Börse Stuttgart
Last update May 01, 2024 at 12:18 am IST
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | MF1J62 |
| ISIN | DE000MF1J629 |
| Date issued | 06/02/2017 |
| Strike | 2,897 kr |
| Maturity | Unlimited |
| Parity | 417.14 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.57 € |
|---|---|
| Lowest since issue | 0.145 € |
| Spread | 0.01 € |
| Spread % | 3.23% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
- Stock Market
- Certificates
- Certificat
